AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
594actual
Sites
158
Countries
Brazil, Canada, China +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-04 | actual | When the study began enrolling |
| Primary completion | 2026-05-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
- Drug: AZD0901 — also filed as Sonesitatug Vedotin
- Drug: AZD0901 — also filed as Sonesitatug Vedotin
- Drug: Ramucirumab+ paclitaxel
- Drug: Paclitaxel
- Drug: Docetaxel
- Drug: Irinotecan
- Drug: TAS-102
- Drug: Apatinib
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS) in all randomized participants
measured From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
Overall Survival (OS) for 3L+ participants
measured From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).
Publications
- PMID 40341124 — linked by the registry
- PMID 39232496 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed